{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:16Z","timestamp":1791919456050,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.lungcan.2008.07.002","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T04:33:03Z","timestamp":1218601983000},"page":"51-59","source":"Crossref","is-referenced-by-count":74,"title":["Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"64","author":[{"given":"Anne M.","family":"Traynor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan H.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura P.","family":"Stabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Marcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2008.07.002_bib1","series-title":"Cancer Facts and Figures 2005","author":"American Cancer Society","year":"2005"},{"key":"10.1016\/j.lungcan.2008.07.002_bib2","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2005.11.486","article-title":"Lung cancer in women","volume":"23","author":"Patel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1378\/chest.127.3.768","article-title":"Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database","volume":"127","author":"Fu","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2008.07.002_bib4","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.1990.8.8.1402","article-title":"Sex-associated differences in presentation and survival in patients with lung cancer","volume":"8","author":"Ferguson","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/annonc\/mdf187","article-title":"Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20561 cases","volume":"13","author":"Radzikowska","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/oxfordjournals.aje.a116857","article-title":"Are female smokers at higher risk for lung cancer than male smokers? A case\u2013control analysis by histologic type","volume":"138","author":"Risch","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2003.08.024","article-title":"Women's susceptibility to tobacco carcinogens","volume":"43","author":"Henschke","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.07.002_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jnci\/95.6.470","article-title":"Variations in lung cancer risk among smokers","volume":"95","author":"Bach","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2008.07.002_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/jnci\/djh143","article-title":"Lung cancer rates in men and women with comparable histories of smoking","volume":"96","author":"Bain","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2008.07.002_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jnci\/92.1.24","article-title":"Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer","volume":"92","author":"Shriver","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2008.07.002_bib11","first-page":"3317","article-title":"Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients","volume":"59","author":"Mollerup","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0169-5002(00)00163-X","article-title":"Gender differences in genetic susceptibility for lung cancer","volume":"30","author":"Dresler","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.07.002_bib13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mc.20128","article-title":"Estrogen receptor \u03b1 increases basal and cigarette smoke extract-induced expression of CYP1A1 and CYP1B1, but not GSTP1, in normal human bronchial epithelial cells","volume":"44","author":"Han","year":"2005","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.lungcan.2008.07.002_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.2005.02.9827","article-title":"Hormone replacement therapy is associated with decreased survival in women with lung cancer","volume":"24","author":"Ganti","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib15","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1200\/JCO.2007.13.3975","article-title":"Reproductive factors, hormone use, estrogen receptor expression and risk of non-small-cell lung cancer in women","volume":"25","author":"Schwartz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0303-7207(01)00750-X","article-title":"Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue","volume":"188","author":"Fasco","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib17","first-page":"2141","article-title":"Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen","volume":"62","author":"Stabile","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib18","doi-asserted-by":"crossref","first-page":"L222","DOI":"10.1152\/ajplung.00384.2006","article-title":"Estrogen receptor-\u03b1 regulated pulmonary alveolar loss and regeneration in female mice: morphometric and gene expression studies","volume":"293","author":"Massaro","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1165\/ajrcmb.20.4.3241","article-title":"Estrogen acutely stimulates endothelial nitric oxide synthase in H441 human airway epithelial cells","volume":"20","author":"Kirsch","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/bbrc.2001.5158","article-title":"Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers","volume":"285","author":"Omoto","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.lungcan.2008.07.002_bib21","doi-asserted-by":"crossref","first-page":"8542","DOI":"10.1128\/MCB.23.23.8542-8552.2003","article-title":"Regulation of postnatal lung development and homeostasis by estrogen receptor beta","volume":"23","author":"Patrone","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib22","first-page":"6002","article-title":"Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors","volume":"9","author":"Spivack","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/0008-5472.CAN-04-1872","article-title":"Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects","volume":"65","author":"Stabile","year":"2005","journal-title":"Cancer Res"},{"issue":"5 Suppl. 16","key":"10.1016\/j.lungcan.2008.07.002_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.seminoncol.2003.08.003","article-title":"Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor","volume":"30","author":"Jones","year":"2003","journal-title":"Seminars Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib25","doi-asserted-by":"crossref","first-page":"H2607","DOI":"10.1152\/ajpheart.01107.2006","article-title":"Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation","volume":"292","author":"Xing","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib26","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/0008-5472.CAN-04-2694","article-title":"Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands","volume":"65","author":"Hershberger","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2007.07.025","article-title":"Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival","volume":"59","author":"Skov","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.07.002_bib28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jtcvs.2005.06.012","article-title":"The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers","volume":"130","author":"Wu","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.lungcan.2008.07.002_bib29","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1158\/1078-0432.CCR-05-0498","article-title":"Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex","volume":"11","author":"Schwartz","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib30","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-05-0200","article-title":"Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer","volume":"11","author":"Kawai","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2008.07.002_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/sj.bjc.6603665","article-title":"Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?","volume":"96","author":"Uramoto","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2008.07.002_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer\u2014molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2008.07.002_bib34","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2008.07.002_bib35","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib36","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib37","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2008.07.002_bib38","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","article-title":"Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib39","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","article-title":"Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer","volume":"25","author":"Herbst","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib40","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","article-title":"Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)","volume":"65","author":"Chinnaiyan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.steroids.2006.11.019","article-title":"Estrogen receptor signaling pathways in human non-small cell lung cancer","volume":"72","author":"Marquez-Garban","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.lungcan.2008.07.002_bib42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.steroids.2005.02.017","article-title":"Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells","volume":"70","author":"Pietras","year":"2005","journal-title":"Steroids"},{"key":"10.1016\/j.lungcan.2008.07.002_bib43","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1210\/me.2004-0439","article-title":"Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells","volume":"19","author":"Boerner","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/me.2002-0368","article-title":"Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor","volume":"17","author":"Levin","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib45","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.12-7-774","article-title":"Fulvestrant (Faslodex) how to make a good drug better","volume":"12","author":"Robertson","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2008.07.002_bib46","first-page":"408","article-title":"Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer","volume":"54","author":"DeFriend","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01243894-200609000-00007","article-title":"Mutation and polymorphism in the EGFR-TK domain associated with lung cancer","volume":"1","author":"Zhang","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib48","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib49","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib50","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","article-title":"Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer","volume":"26","author":"Socinski","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.lungcan.2008.07.002_bib51","first-page":"364s","article-title":"Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma","volume":"24","author":"Gatzemeier","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib52","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2008.07.002_bib54","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non\u2013small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib55","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjc.6603393","article-title":"A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations","volume":"95","author":"Asahina","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2008.07.002_bib56","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1073\/pnas.88.1.21","article-title":"Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation","volume":"88","author":"Nelson","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lungcan.2008.07.002_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1210\/me.16.1.70","article-title":"Estrogen action via the G protein-coupled receptor. GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis","volume":"16","author":"Filardo","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.lungcan.2008.07.002_bib59","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-07-1373","article-title":"Membrane-associated estrogen receptor signaling pathways in human cancers","volume":"13","author":"Pietras","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.07.002_bib60","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1210\/en.2002-220620","article-title":"Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells","volume":"144","author":"Knowlden","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.lungcan.2008.07.002_bib61","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1210\/en.142.7.2776","article-title":"Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex)","volume":"142","author":"McClelland","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.lungcan.2008.07.002_bib62","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0960-0760(90)90424-J","article-title":"Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure","volume":"37","author":"Nicholson","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl.","key":"10.1016\/j.lungcan.2008.07.002_bib63","first-page":"713s","article-title":"Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC)","volume":"26","author":"Garon","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208003681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208003681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T04:43:06Z","timestamp":1557722586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500208003681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0169500208003681"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2008.07.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}